Drug Profile


Alternative Names: Am-555S; TAC-101

Latest Information Update: 08 Apr 2011

Price : $50

At a glance

  • Originator Taiho Pharmaceutical
  • Class Antineoplastics; Benzoic acids; Retinoids; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Retinoic acid receptor alpha antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Hepatocellular carcinoma

Most Recent Events

  • 17 Mar 2011 Discontinued - Phase-II for Hepatocellular carcinoma in Japan (PO)
  • 17 Mar 2011 Discontinued - Phase-II for Hepatocellular carcinoma in Italy (PO)
  • 22 Jul 2009 Suspended - Phase-II for Hepatocellular carcinoma in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top